PolyBio

From Crisis to Cure: PolyBio is supporting top HIV researchers to pivot into the study and treatment of Long COVID. Watch the full video to learn how this collaboration is being maximized & driving forward innovative research: youtu.be/6kC1lyY6hPc?si…

Learn more about PolyBio’s Long COVID Diagnostics Commercialization Advisory Network: polybio.org/polybio-commer…

Dr. Amy Proal in collaboration with the CoRE Clinic this week: “A big goal of ours is that [Long COVID] diagnostics are available to be ordered in insurance care for the most number of patients. You have to choose a different regulatory route and that requires a lot of interactions with the FDA, a lot of validation experiments… This incubation process of getting the diagnostic out of academia and into the real world, that’s something we’ve been working on a lot.”

Watch the full Q & A recording here: youtube.com/live/oHJEo0KIB…

Tonight in Boston: Dr. Amy Proal is speaking with the Boston Health Innovation Community to address novel ways of clearing persistent infections and parasites for longevity. To those in the area—come out to watch this one-of-a-kind talk in person at 6:30 pm. We can’t wait to see you there! luma.com/5czm4fx9

4/ Eligibility criteria: -You have been formally diagnosed with Long COVID by a physician -You are 18 years or older -You live in New York and can travel to in-person clinic visits (NOTE: severe patients with restricted travel may be eligible for some at-home visits—reach out to the trial team for more information) Email CoreResearch@MountSinai.org to register.

3/ Now, with the addition of an open-label phase, participants can opt to receive the drug after the 3 month trial period is completed—even if they were initially randomized to placebo.

Mount Sinai’s CoRE Clinic is recruiting participants for a clinical trial of low-dose Rapamycin for Long COVID. The major focus of this trial is to determine which LC patient subtypes benefit most from the drug. Your participation will help researchers better understand targeted immune modulating therapies for infection-associated chronic illnesses. More information & eligibility details👇🏻

TODAY at 4:30 pm EST: Watch the Q & A livestream with the Cohen Center for Recovery from Complex Chronic Illness featuring Dr.s Amy Proal and David Putrino. Get your questions ready! Livestream will take place on the @CoRESinai accounts & a recording will be available.

PolyBio publishes a monthly newsletter that features our latest articles, research findings, and interviews with partner researchers. Sign up now to stay updated on the research that’s driving forward discovery in Long COVID, ME/CFS, and other IACIs. polybio.org/newsletter/

Catch Dr. Amy Proal, PolyBio President and Scientific Director of the CoRE Clinic, on next Wednesday’s Q & A livestream with the Cohen Center for Recovery from Complex Chronic Illness. The livestream welcomes broad questions surrounding IACIs, including new research, current therapeutic approaches, and more. Get your questions ready & mark your calendar for July 15th at 4:30 pm ET! Livestream available via X 👉🏻 @CoRESinai

3/ Listen to Dr. Marcelo Freire’s full symposium presentation here: youtu.be/tD5gWVEjudQ?t=…

2/ PolyBio is supporting this project investigating the oral cavity as a window into the identification of Long COVID immune, clotting, microbiome, and viral protein biomarkers. The team is using shotgun proteomics to identify persistent innate immune and clotting dysfunction in saliva collected from Long COVID patients and matched controls. Similar analyses are also being performed on patient blood to determine the degree to which Long COVID saliva biomarkers mirror those in the systemic circulation. polybio.org/projects/long-…

Dr. Marcelo Freire and his team are leading efforts to implement Salivary Proteomics into Long COVID clinical trials as primary endpoints. In a recent Mount Sinai-based trial of Vagus Nerve Stimulation for LC, this noninvasive method suggested a significant difference in inflammatory responses between treatment and sham groups over 12 weeks. Persistently upregulated salivary proteins in the sham group included serum amyloid A4 protein. “The clinical significance of proteins like these present in saliva is… it corresponds to an increased relationship in rheumatoid arthritis, oncology & atherosclerosis,” said Freire. Whereas the active VNS treatment group demonstrated consistent downregulation of several inflammatory markers, including gamma-synuclein, sometimes connected to neurodegenerative disease, as well as breast & colorectal cancer.

It's madness that most people in the healthspan-extension space do little to control the activity of #viral, bacterial, #parasite and other pathogens that can hack their bodies over time. Come listen to me talk at the Liberty Hotel next Thurs where I will discuss how to change this by optimizing anti-pathogen treatment approaches! eventbrite.com/e/health-innov…

Watch Dr. Van Brocklin’s full symposium presentation here: youtu.be/tD5gWVEjudQ?t=…

The team is continuing to validate T cell activation via [18F]F-AraG as a potential biomarker of inflammation in clinical trials within PolyBio’s network, including the current UCSF-based trial of Ensitrelvir for Long COVID. This research will help determine the degree to which the therapeutics are successfully lowering Long COVID-associated inflammation. 3/

Dr. Henry Van Brocklin and his UCSF team are investigating the novel radiotracer [18F]F-AraG as a biomarker of long-term immune dysregulation in Long COVID. When paired with PET imaging, the tracer has shown persistent T cell activation in tissues such as the brain, lungs, gut, spinal cord & bone marrow. “Even in cases where the Long COVID symptoms were not associated with the [organ] phenotype, we actually saw elevation there,” said Van Brocklin. The method is actively being tested in a clinical trial of Ensitrelvir for Long COVID to determine measurable changes in immune activation following treatment versus placebo.

The deep analysis of microclot components will assist in determining the correct combination of therapeutic drugs (i.e. antimicrobial or antiviral drugs with antibrinolytic or anticoagulant therapies) in Long COVID clinical trials aimed at microclot disruption. 3/

The PolyBio-supported research project discussed by Dr. Pretorius is investigating the degree to which viral proteins or bacterial products contribute to the composition of Long COVID fibrinaloid microclots. Fibrinaloid microclots are being isolated from the blood of Long COVID study participants and assessed via metatranscriptomic sequencing and advanced proteomics. 2/ polybio.org/projects/analy…

Said Dr. Resia Pretorius on differentiating microclot components between Long COVID, ME/CFS and POTS: “If we can understand the protein content associated with these amyloidygenic molecules, we think we might be able to identify, in that [insoluble plasma] fraction, proteins that we can target. “In this proteomics analysis specifically, we are finding a lot of post-translational modifications. We are finding molecules suggesting there’s complement activation, neutrophil activation… If you really deep dive into the sequence of the peptides of the proteins in the structures, then a whole new world opens up.” 1/ youtu.be/zPtsXBbQkUc?si…